Mainboard
IPO ·
BSE, NSE
Molbio Diagnostics Ltd
Listed
Incorporated in October 2000, Molbio Diagnostics Limited is a global point-of-care (POC) molecular diagnostics company engaged in the research, development, manufacturing, and commercialization of rapid diagnostic solutions for in
Issue details
Price band
₹768 – ₹807
Face value
₹1
Lot size
18 shares
Minimum investment
₹14,526
Issue size
₹939.70 Cr
Fresh issue
₹200.12 Cr
Offer for sale
₹739.57 Cr
Issue type
Book Built
Exchange
BSE, NSE
Key dates
Opens
10 Aug 2026
Closes
12 Aug 2026
UPI mandate cut-off
5:00 PM on 12 Aug 2026
Allotment
13 Aug 2026
Refunds
14 Aug 2026
Shares in demat
14 Aug 2026
Listing
17 Aug 2026
Subscription and listing
Subscription
49.35x
Listing price
₹980
Registrar
Kfin Technologies Ltd
Lead manager
Kotak Mahindra Capital Co., IIFL Capital Services, Jefferies India, Motilal Oswal Investment Advisors
Subscription by category
Total
49.35x
Total applications
26,07,201
Anchor investors
Amount raised
₹281.46 Cr
Bid date
7 Aug 2026
50% lock-in ends
11 Sep 2026
Rest lock-in ends
10 Nov 2026
Listing day
Issue price
₹807
Open
₹980.00
High
₹1,064.75
Low
₹926.35
Day close
₹1,041.70
Listing gain at open
+21.44%
Issue structure
Shares reserved per category and share of the total issue
QIB
58,12,862
49.91%
Anchor Investor
34,87,717
29.95%
QIB (Ex. Anchor)
23,25,145
19.96%
NII
17,43,860
14.97%
bNII > ₹10L
11,62,573
9.98%
sNII < ₹10L
5,81,287
4.99%
Retail
40,69,005
34.94%
Employee
20,519
0.18%
Total
1,16,46,246
100.00%
Finaccle’s quick read
Apply for long term
FY26 income up 42%, PAT up 18%, ROE 15.59%, post-issue P/E 56.67x.
A rules-based screen of growth, margins, debt and valuation, built from the offer document and data on Chittorgarh.com. It is for information only and is not investment advice or a recommendation to buy or sell. Read the RHP and speak to a SEBI-registered adviser before you apply.
About the company
Incorporated in October 2000, Molbio Diagnostics Limited is a global point-of-care (POC) molecular diagnostics company engaged in the research, development, manufacturing, and commercialization of rapid diagnostic solutions for infectious and non-communicable diseases. The company has developed its proprietary 'Truenat' platform, a portable, battery-operated PCR-based molecular diagnostics system designed for resource-limited settings, offering accurate test results within an hour. Molbio offers molecular testing solutions for over 30 diseases through 43 diagnostic assays, including tuberculosis (TB), COVID-19, HIV, Hepatitis B & C, and HPV.
Founded
Promoters
Promoter holding
Financial performance
Period
PAT
ROE
15.59%
ROCE
17.55%
Debt / equity
—
PAT margin
11.28%
P/E post issue
56.67
Market cap
₹9,299.87 Cr
Use of IPO money
Funding capital expenditure towards the setting up of infrastructure for research and development facility, Center of Excellence and connected office space.
₹105.54 Cr
Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit, and
₹72.28 Cr
General Corporate Purposes
₹9.47 Cr
Issue Expenses
₹59.54 Cr
Strengths
✓
Revenue up 42% in FY26 to ₹1,455.17 Cr
✓
PAT up 18% in FY26 to ₹164.14 Cr
✓
PAT margin of 11.28%
✓
ROE of 15.59% and ROCE of 17.55%
Risks to watch
!
Rich valuation: post-issue P/E of 56.67x
!
79% of issue is an offer for sale; company gets less fresh money
Planning to take your own company public?
Every listing on this page started with a growing business that got its numbers, governance and paperwork ready for investors. If you are a promoter weighing an SME or main board IPO, we can tell you where you stand and what it will take.
Talk to our IPO Advisory team for readiness planning, or our IPO Consultancy team to run the listing end to end.
Last updated:
Information is compiled from exchange notices and the company’s offer document. It is for general information only and is not investment advice or a recommendation to apply. Read the prospectus before investing.